Active Recombinant Full Length Human CDK9 Protein, DDK-tagged, Biotinylated

• Cat.No.: CDK9-9833HF
• Product Overview: Full-length human CDK9 [1-372(end) amino acids of accession number NP_001252.1] was co-expressed as N-terminal DYKDDDDK tagged, biotinylated protein (47 kDa) with His-CyclinT1 [1-726(end) amino acids of accession number NP_001231.2] using baculovirus expression system. The protein was purified by using DYKDDDDK tag antibody agarose.

Specification

• Source: Insect (sf21)
• Species: Human
• Tag: DDK
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was measured by off-chip mobility shift assay(MSA). The enzyme was incubated with fluorecence-labeled substrate and Mg(or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by MSA device.
• Protein length: 1-372(end)
• Purity: 95%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: cyclin-dependent kinase 9
• Official Symbol: CDK9
• Synonyms: CDK9;C-2k;CDC2L4;CTK1;PITALRE;TAK
• Protein Refseq: NP_001252.1
• UniProt ID: P50750

Reviews

08/31/2020

Its remarkable quality, versatility, and the manufacturer's commitment to customer satisfaction make it the perfect choice for researchers seeking a premier protein that will undoubtedly enhance their experimental endeavors.

06/26/2019

In addition to its remarkable quality and exceptional technical support, the CDK9 Protein boasts an impressive range of applications.

09/12/2018

The CDK9 Protein has exceeded my expectations by consistently delivering outstanding results and providing exceptional technical support.

Q&As

Is CDK9 targeted only for cancer and antiviral therapies, or are there other applications?

Besides cancer and antiviral therapies, CDK9 is being explored for its role in other diseases, including neurodegenerative disorders.

Can CDK9 inhibitors be used in combination with other cancer treatments?

Yes, combination therapies involving CDK9 inhibitors and other drugs are being investigated to enhance treatment outcomes.

How does the expression of CDK9 vary in different stages of cancer progression?

CDK9 expression tends to increase as cancer progresses, suggesting its potential as a biomarker for disease severity.

How does CDK9 inhibition affect normal cellular functions?

CDK9 inhibitors can impact normal cell functions, leading to potential side effects such as myelosuppression.

Are there ongoing clinical trials involving CDK9 inhibitors?

Yes, several clinical trials are exploring the effectiveness of CDK9 inhibitors in different cancer types.